Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer - Tolaney, S; Kalinsky, K; Kaklamani, V (Cancer Res, 2018)